- Home
- KNDI vs AGEN Comparison
KNDI vs AGEN Comparison
Compare KNDI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNDI
- AGEN
- Stock Information
- Founded
- KNDI 2002
- AGEN 1994
- Country
- KNDI China
- AGEN United States
- Employees
- KNDI N/A
- AGEN N/A
- Industry
- KNDI Auto Manufacturing
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KNDI Consumer Discretionary
- AGEN Health Care
- Exchange
- KNDI Nasdaq
- AGEN Nasdaq
- Market Cap
- KNDI 96.3M
- AGEN 87.7M
- IPO Year
- KNDI N/A
- AGEN 2000
- Fundamental
- Price
- KNDI $1.27
- AGEN $6.15
- Analyst Decision
- KNDI
- AGEN Buy
- Analyst Count
- KNDI 0
- AGEN 4
- Target Price
- KNDI N/A
- AGEN $13.00
- AVG Volume (30 Days)
- KNDI 134.9K
- AGEN 1.5M
- Earning Date
- KNDI 08-15-2025
- AGEN 08-07-2025
- Dividend Yield
- KNDI N/A
- AGEN N/A
- EPS Growth
- KNDI N/A
- AGEN N/A
- EPS
- KNDI N/A
- AGEN N/A
- Revenue
- KNDI $127,569,613.00
- AGEN $99,524,000.00
- Revenue This Year
- KNDI N/A
- AGEN $25.31
- Revenue Next Year
- KNDI N/A
- AGEN N/A
- P/E Ratio
- KNDI N/A
- AGEN N/A
- Revenue Growth
- KNDI 3.21
- AGEN N/A
- 52 Week Low
- KNDI $0.89
- AGEN $1.38
- 52 Week High
- KNDI $2.07
- AGEN $8.70
- Technical
- Relative Strength Index (RSI)
- KNDI 63.81
- AGEN 56.41
- Support Level
- KNDI $1.09
- AGEN $6.12
- Resistance Level
- KNDI $1.30
- AGEN $6.96
- Average True Range (ATR)
- KNDI 0.06
- AGEN 0.72
- MACD
- KNDI 0.01
- AGEN 0.06
- Stochastic Oscillator
- KNDI 86.36
- AGEN 60.33
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).